Stock Rating Upgrade
Reflecting improving fundamentals and high Appreciation Potential, the Value Trend Rating for Neurocrine Biosciences Inc (NASDAQ: NBIX) improved of late. NBIX’s current Value Trend Rating is B and the prior Rating was C. Details supporting this higher rating are included in our next report.
Recent Price Action
On 1/12/24, Neurocrine Biosciences Inc (NASDAQ: NBIX) stock increased 1.1%, closing at $132.03. However, this advance was accompanied by below average trading volume at 76% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -1.2% during the last week.
Current PriceTarget Research Rating
NBIX is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Neurocrine Biosciences has a current Value Trend Rating of B (Positive). This VT Rating improved in recent days from C previously. With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. Neurocrine Biosciences has a neutral Appreciation Score of 42 but a very high Power Rating of 87, resulting in the Positive Value Trend Rating.
Be the first to comment